Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
fusidic acid · 1 trial · 1 indication
Skin rash was assessed by the investigator and dermatologists (the latter ones only through pictures) and scored according to (National cancer Institute -Common Terminology Criteria for Adverse Events ) NCI-CTCAE ( version 3 (line "Rash/desquamation" - short name "rash").
The severity of skin rash was graded on a 5 point scale where 0 (equals)= absent, 1= mile, 2=moderate, 3= severe, 4= life threatening and 5= Death
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | EXPERIMENTAL | - |
| 3 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| erlotinib [Tarceva] | DRUG | 150mg po daily |
| fusidic acid [Verutex] | DRUG | topical, daily for 30 days. |
| erythromycin [Eritex] | DRUG | topical, daily for 30 days. |
| Fisiogel | DRUG | topical, daily for 30 days |
Inclusion Criteria: * adult patients, \>=18 years of age; * locally advanced or metastatic non-small cell lung cancer (stage IIIB/IV); * eligible to start treatment with Tarceva, or receiving Tarceva for \<=5 days. Exclusion Criteria: * presence of skin rash or other signs of skin toxicity; * tre...
Top 20 of 84 competitors
Fusidic acid is an investigational small molecule being studied for use in Non-Small Cell Lung Cancer (NSCLC). It is being evaluated in a Phase 3 clinical trial for the management of Tarceva-associated rash in patients with NSCLC. The drug is not yet approved and remains in clinical development.
Fusidic acid is a small molecule antibiotic that works by inhibiting bacterial protein synthesis. In the context of the Phase 3 trial, it is being studied for its potential to manage skin rash associated with Tarceva (erlotinib) treatment in Non-Small Cell Lung Cancer patients. The specific molecular target in this oncology setting is not detailed.
Fusidic acid is being developed by Roche Holding AG, which trades under the ticker RHHBY. The company is conducting a Phase 3 clinical trial of the drug for Non-Small Cell Lung Cancer. Roche is responsible for the ongoing clinical development of fusidic acid.
Fusidic acid is currently in Phase 3 clinical development. It is being studied in a completed Phase 3 trial for Non-Small Cell Lung Cancer, specifically for the management of Tarceva-associated rash. The drug is investigational and has not been approved for this indication.
Fusidic acid has one completed Phase 3 clinical trial registered as NCT00718315. This study, titled 'A Study of Verutex (Fusidic Acid), Eritex (Erythromycin) and Fisiogel in the Management of Tarceva-Associated Rash,' enrolled 201 participants with Non-Small Cell Lung Cancer in Brazil. The trial was controlled but not double-blinded.
Yes, fusidic acid is also known as Verutex. In the clinical trial NCT00718315, the drug is referred to as Verutex (Fusidic Acid). This alternative name is used in the study title for the management of Tarceva-associated rash in Non-Small Cell Lung Cancer patients.